Azenta, Inc.

NASDAQ:AZTA

Medical - Instruments & Supplies

Healthcare
$48.69 -0.11%

-$0.03 today

Market cap
$2.13B
Beta
1.40
P/E (TTM)
-5.9
EPS (TTM)
-$3.87
52W Low $15.93High $41.73

Volume 0.69M

Average 1.16M

AZTA Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Azenta, Inc.NASDAQ: AZTA

Cost of Revenue · Q4 FY2026 · quarter ended Sep 2026

Cost of revenue grows, but more slowly than its trailing trend

Q4 FY2026 cost of revenue of $90.22M rose 3.8% year over year, behind the +8.6% change in trailing-twelve-month cost of revenue. Sequentially, it rose 1.6% from the prior quarter. Over 3 fiscal years it compounded at -7.1% a year.

Context

  • Cost of revenue amounted to 55.8% of revenue in FY2026, up 1.3 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +3.8% toward the trailing-twelve-month pace of +8.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$90.22M+1.6% QoQ
Last fiscal yearSep 2026
$346.74M+7.2% YoY
LTMSep 2026
$346.74M+8.6% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+3.8%——
1 year+7.2%——
3-year CAGR-7.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2026
346.74M USD
Year-over-year change
+7.2%
4-year CAGR
+1.6%

Cost of Revenue vs competitors

How AZTA compares with its peers on the latest reported figures

  • AZTA's LTM Sep 2026 cost of revenue of $346.74M is the 8th highest of the 10 companies compared; the peer median is $1.25B.
  • Its year-over-year change of +8.6% is the 2nd highest of 10, against a peer median of +2.6%.
  • Cost of revenue amounts to 55.8% of revenue for AZTA, versus a peer median of 45.3%.
AZTA Competitors Peer median
Cost of Revenue for AZTA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$27.73B +6.5%+0.5%58.6%
DHRDanaher CorporationLTM Sep 2026$10.6B +12.9%-2.8%41.4%
SOLVSolventum CorporationLTM Jun 2026$3.77B -1.3%+4.1%45.3%
BRKRBruker CorporationLTM Jun 2026$1.87B +4.7%+14.9%53.3%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$1.25B +3.4%+0.1%48.1%
NEOGNeogen CorporationLTM Aug 2026$465.01M -11.0%+3.5%52.6%
TECHBio-Techne CorporationLTM Sep 2026$420.61M -0.2%+4.3%34.2%
AZTAAzenta, Inc.LTM Sep 2026$346.74M +8.6%-7.1%55.8%
MLABMesa Laboratories, Inc.LTM Mar 2026$90.86M +0.8%+2.1%36.5%
BLFSBioLife Solutions, Inc.LTM Mar 2026$36.03M +2.6%+5.1%36.1%
Peer median (excluding AZTA) $1.25B+2.6%+3.5%45.3%

Competitors are the stored peer set for AZTA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue555.5M665.07M573.45M593.82M621.7M
Cost of Revenue324.88M431.82M318.83M323.54M346.74M
Gross Profit230.62M233.26M254.62M270.28M274.96M
Gross Margin41.5%35.1%44.4%45.5%44.2%
Research & Development27.54M33.96M31.52M30.39M37.92M
Selling, General & Admin227.1M281.5M253.08M251.16M257.53M
Operating Expenses254.64M315.45M284.6M281.55M449.66M
Depreciation & Amortization53.7M85.58M90.74M61.21M0
EBITDA48.36M55.15M71.62M54.07M(151.01M)
EBITDA Margin8.7%8.3%12.5%9.1%-24.3%
Operating Income(24.02M)(82.2M)(29.98M)(11.27M)(174.7M)
Operating Margin-4.3%-12.4%-5.2%-1.9%-28.1%
Interest Income20.29M43.74M33.18M18.78M17.83M
Interest Expense4.59M0000
Other Income / Expenses14.09M51.77M10.86M4.13M23.69M
Income Before Tax(9.94M)(30.43M)(19.13M)(7.14M)(151.01M)
Pre-Tax Margin-1.8%-4.6%-3.3%-1.2%-24.3%
Income Tax Expense1.35M(17.55M)5.24M(31.6M)6.86M
Net Income(428.96M)(14.26M)(164.9M)(55.76M)(166.99M)
Net Margin-77.2%-2.1%-28.8%-9.4%-26.9%
EPS (Basic)(0.15)(0.22)(3.09)(1.22)(3.70)
EPS (Diluted)(0.15)(0.22)(3.09)(1.22)(3.70)
Weighted Avg Shares74.9M66.25M53.18M45.74M45.13M
Weighted Avg Shares (Diluted)74.9M66.25M53.18M45.9M45.13M

Azenta, Inc.

NASDAQ:AZTA

Intrinsic Alpha fair value

Locked

Current Price

$48.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.